ClinicalTrials.gg
CompletedNCT05678998Updated Jan 6, 2026Results posted

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

A Phase 1 interventional study of WTX-330 in Advanced or Metastatic Solid Tumors and Non-Hodgkin Lymphoma, sponsored by Werewolf Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Werewolf Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 253 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
846th of 1,378
25 · median 35
Started
2022
with 54 others
Phase 1
529 of 1,600
48 open now
Registered
1,491st of 1,600
by date

Among the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 846th largest by enrollment of the 1,378 interventional ones that give a count, is one of 55 that started in 2022, is one of 529 in phase 1, and was the 1,491st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

137 of the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Read the detailed description

This is a first-in-human, Phase 1, open-label, multicenter study to evaluate the safety, tolerability and preliminary efficacy of WTX-330, a conditionally-activated IL-12 prodrug, when administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. Dose escalation will be conducted in patients with advanced and/or metastatic solid tumors who are refractory to all standard of care therapies. Dose expansion will be conducted in two arms: Arm A will enroll patients with indications for which a checkpoint inhibitor (CPI) is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1 treatment regimen, and Arm B will enroll patients with tumor types for which CPI therapy is not indicated/approved.

03

Conditions studied

  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma

Keywords

  • WTX-330
  • Cancer
  • Immunotherapy
  • Interleukin-12
  • IL-12
  • Checkpoint inhibitor resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Dose Escalation: A diagnosis of a advanced or solid tumor for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists.
  3. Dose Expansion: A diagnosis of a relapsed/refractory advanced or metastatic for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. For Arm A, patients must have a tumor type for which a CPI is indicated/approved and demonstrate primary or secondary resistance to a standard of care anti-PD(L)1-based treatment regimen. For Arm B, patients must have a solid tumor type for which a CPI is not indicated/approved or non-Hodgkin lymphoma.
  4. (ECOG) Performance Status of 0 or 1.
  5. At least one per 1.1 or an evaluable lesion per Lugano classification (for lymphoma).
  6. Agrees to undergo a pre-treatment and on-treatment of a primary or metastatic solid tumor or lymphoma lesion.
  7. -infected patients must be on antiretroviral therapy and have well-controlled disease.
  8. Adequate organ and bone marrow function.
  9. Willingness of men and women of to use highly effective for the duration of treatment and for 4 months following the last dose of study drug.
  10. Additional criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. A history of another active (i.e., a second cancer) within the previous 2 years, except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, present a low risk of recurrence. These exceptions include but are not limited to basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  2. Received prior treatment with IL-12, including by intratumoral injection.
  3. Patients with primary CNS malignancies.
  4. Presence of that are symptomatic and/or require local CNS directed therapy (such as XRT or surgery) or increasing doses of within 2 weeks prior to the first dose of study drug. Patients with treated brain metastases should be neurologically stable and receiving ≤ 10 mg per day of prednisone or equivalent prior to study entry.
  5. Significant cardiovascular disease.
  6. Significant (ECG) abnormalities
  7. Active disease requiring systemic treatment in the past 2 years.
  8. Diagnosis of immunodeficiency, on therapy, or receiving chronic systemic or enteric steroid therapy (dose > 10 mg/day of prednisone or equivalent).
  9. Prior receipt of an stem cell transplant or allogeneic CAR-T cell therapy.
  10. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug.
  11. agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine, or anticancer herbal remedy) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug.
  12. Radiotherapy within 2 weeks of the start of study treatment. A 1-week is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
  13. Any unresolved toxicities from prior therapy greater than version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 platinum therapy-related neuropathy.
  14. Use of sensitive substrates of major CYP450 isozymes.
  15. Any illness, medical condition, organ system dysfunction, or social situation (including mental illness or substance abuse), that may interfere with a patient's ability to sign the ICF, adversely affect the patient's ability to cooperate and participate in the study, or compromise interpretation of study results.
  16. Received a within 30 days of the first dose of study drug.
  17. Active, uncontrolled systemic bacterial, viral, or fungal infection.
  18. -infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  19. Active infection with as determined by hepatitis B surface antigen and hepatitis B core antibody, or hepatitis B virus deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (qPCR) testing.
  20. Active infection with as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing.
  21. Pregnant or lactating.
  22. History of to any of the study drug components.
  23. Additional criteria may apply
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    WTX-330 dose escalation

    Patients with relapsed/refractory advanced or metastatic solid tumors

    Drug: WTX-330

  • Experimental
    WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A)

    WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen

    Drug: WTX-330

  • Experimental
    WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B)

    WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved

    Drug: WTX-330

Interventions

  • DrugWTX-330

    Investigation Product

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs)

    A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol

    Time frame: 4 weeks

  2. Incidence of Treatment Emergent Adverse Events

    AEs were graded and documented in accordance with NCI-CTCAE version 5.0

    Time frame: 24 months

  3. Incidence of Changes in Clinical Laboratory Abnormalities

    Change from baseline is provided as baseline grade or "normal/low/high" and worst post-baseline grade.

    Time frame: 24 months

  4. Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)

    RECIST = Response Evaluation Criteria in Solid Tumors

    Time frame: 24 months

Secondary outcomes

  1. Plasma Concentrations of WTX-330 Cycle 1 - C Max

    PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  2. Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation

    PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  3. Plasma Concentrations of WTX-330 Cycle 1 - Half Life

    PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  4. Plasma Concentrations of WTX-330 Cycle 1 - AUC

    PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

    Time frame: 14 days

  5. Plasma Concentrations of WTX-330 Cycle 2 - C Max

    PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  6. Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation

    PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  7. Plasma Concentrations of WTX-330 Cycle 2 - Half Life

    PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  8. Plasma Concentrations of WTX-330 Cycle 2 - AUC

    PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

    Time frame: 14 days

  9. Plasma Concentrations of IL-12 Cycle 1 - C Max

    PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  10. Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation

    PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  11. Plasma Concentrations of IL-12 Cycle 1 - Half Life

    PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

  12. Plasma Concentrations of IL-12 Cycle 1 - AUC

    PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

    Time frame: 14 days

  13. Plasma Concentrations of IL-12 Cycle 2 - C Max

    PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  14. Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation

    PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  15. Plasma Concentrations of IL-12 Cycle 2 - Half Life

    PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

    Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

  16. Plasma Concentrations of IL-12 Cycle 2 - AUC

    PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

    Time frame: 14 days

  17. Antidrug Antibody (ADA) Occurrence

    ADA were measured at Baseline and Post Baseline. "Positive" post baseline applies if at least one post-baseline value was positive.

    Time frame: 24 months

07

Results

Posted Jan 6, 2026

Participant flow

Participants were recruited based on their oncological history at 9 clinical research sites in the United States.

Participant flow — Overall Study
MilestoneWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg
Started33559
Completed22202
Not completed11357
Withdrew: Withdrawal by subject11301
Withdrew: Lost to follow-up00001
Withdrew: Death00034
Withdrew: Other00021

Outcome measures

PrimaryIncidence of Dose Limiting Toxicities (DLTs)

A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Incidence of Dose Limiting Toxicities (DLTs)
ParticipantsWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Incidence of Dose Limiting Toxicities (DLTs)001
PrimaryIncidence of Treatment Emergent Adverse Events

AEs were graded and documented in accordance with NCI-CTCAE version 5.0

Time frame:
24 months
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events
ParticipantsWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A)WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B)
TEAE33559
TEAEs Related to WTX-33033559
Grade 3 or Higher TEAEs13448
Grade 3 or Higher TEAEs Related to WTX-33012435
Serious TEAEs01238
Serious TEAEs Related to WTX-33001115
PrimaryIncidence of Changes in Clinical Laboratory Abnormalities

Change from baseline is provided as baseline grade or "normal/low/high" and worst post-baseline grade.

Time frame:
24 months
Reported as:
Count of participants · Participants
Incidence of Changes in Clinical Laboratory Abnormalities
ParticipantsWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A)WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B)
Anemia — Grade 0 - Grade 000010
Anemia — Grade 0 - Grade 100300
Anemia — Grade 0 - Grade 200000
Anemia — Grade 0 - Grade 300001
Anemia — Grade 1 - Grade 000000
Anemia — Grade 1 - Grade 120113
Anemia — Grade 1 - Grade 212004
Anemia — Grade 1 - Grade 301010
Anemia — Grade 2 - Grade 000000
Anemia — Grade 2 - Grade 100000
Anemia — Grade 2 - Grade 200111
Anemia — Grade 2 - Grade 300010
Anemia — Grade 3 - Grade 000000
Anemia — Grade 3 - Grade 100000
Anemia — Grade 3 - Grade 200000
Anemia — Grade 3 - Grade 300000
Anemia — Grade 4 - Grade 000000
Anemia — Grade 4 - Grade 100000
Anemia — Grade 4 - Grade 200000
Anemia — Grade 4 - Grade 300000
Anemia — Grade 4 - Grade 400000
Anemia — Grade 0 - Grade 400000
Anemia — Grade 1 - Grade 400000
Anemia — Grade 2 - Grade 400000
Anemia — Grade 3 - Grade 400000
Anemia — Missing00000
Anemia — Low - Grade 000000
Anemia — Normal - Grade 000000
Anemia — Normal - Grade 100000
Anemia — Normal - Grade 200000
Anemia — Normal - Grade 300000
Anemia — High - Grade 000000
Anemia — High - Grade 100000
Anemia — High - Grade 200000
Anemia — High - Grade 300000
Hypoalbuminemia — Grade 0 - Grade 010220
Hypoalbuminemia — Grade 0 - Grade 122206
Hypoalbuminemia — Grade 0 - Grade 201000
Hypoalbuminemia — Grade 0 - Grade 300000
Hypoalbuminemia — Grade 1 - Grade 000000
Hypoalbuminemia — Grade 1 - Grade 100000
Hypoalbuminemia — Grade 1 - Grade 200113
Hypoalbuminemia — Grade 1 - Grade 300000
Hypoalbuminemia — Grade 2 - Grade 000000
Hypoalbuminemia — Grade 2 - Grade 100000
Hypoalbuminemia — Grade 2 - Grade 200020
Hypoalbuminemia — Grade 2 - Grade 300000
Hypoalbuminemia — Grade 3 - Grade 000000
Hypoalbuminemia — Grade 3 - Grade 100000
Hypoalbuminemia — Grade 3 - Grade 200000
Hypoalbuminemia — Grade 3 - Grade 300000
Hypoalbuminemia — Grade 4 - Grade 000000
Hypoalbuminemia — Grade 4 - Grade 100000
Hypoalbuminemia — Grade 4 - Grade 200000
Hypoalbuminemia — Grade 4 - Grade 300000
Hypoalbuminemia — Grade 4 - Grade 400000
Hypoalbuminemia — Grade 0 - Grade 400000
Hypoalbuminemia — Grade 1 - Grade 400000
Hypoalbuminemia — Grade 2 - Grade 400000
Hypoalbuminemia — Grade 3 - Grade 400000
Hypoalbuminemia — Missing00000
Hypoalbuminemia — Low - Grade 000000
Hypoalbuminemia — Normal - Grade 000000
Hypoalbuminemia — Normal - Grade 100000
Hypoalbuminemia — Normal - Grade 200000
Hypoalbuminemia — Normal - Grade 300000
Hypoalbuminemia — High - Grade 000000
Hypoalbuminemia — High - Grade 100000
Hypoalbuminemia — High - Grade 200000
Hypoalbuminemia — High - Grade 300000
Hypoglycemia — Grade 0 - Grade 032558
Hypoglycemia — Grade 0 - Grade 101000
Hypoglycemia — Grade 0 - Grade 200000
Hypoglycemia — Grade 0 - Grade 300000
Hypoglycemia — Grade 1 - Grade 000001
Hypoglycemia — Grade 1 - Grade 100000
Hypoglycemia — Grade 1 - Grade 200000
Hypoglycemia — Grade 1 - Grade 300000
Hypoglycemia — Grade 2 - Grade 000000
Hypoglycemia — Grade 2 - Grade 100000
Hypoglycemia — Grade 2 - Grade 200000
Hypoglycemia — Grade 2 - Grade 300000
Hypoglycemia — Grade 3 - Grade 000000
Hypoglycemia — Grade 3 - Grade 100000
Hypoglycemia — Grade 3 - Grade 200000
Hypoglycemia — Grade 3 - Grade 300000
Hypoglycemia — Grade 4 - Grade 000000
Hypoglycemia — Grade 4 - Grade 100000
Hypoglycemia — Grade 4 - Grade 200000
Hypoglycemia — Grade 4 - Grade 300000
Hypoglycemia — Grade 4 - Grade 400000
Hypoglycemia — Grade 0 - Grade 400000
Hypoglycemia — Grade 1 - Grade 400000
Hypoglycemia — Grade 2 - Grade 400000
Hypoglycemia — Grade 3 - Grade 400000
Hypoglycemia — Missing00000
Hypoglycemia — Low - Grade 000000
Hypoglycemia — Normal - Grade 000000
Hypoglycemia — Normal - Grade 100000
Hypoglycemia — Normal - Grade 200000
Hypoglycemia — Normal - Grade 300000
Hypoglycemia — High - Grade 000000
Hypoglycemia — High - Grade 100000
Hypoglycemia — High - Grade 200000
Hypoglycemia — High - Grade 300000
Hypokalemia — Grade 0 - Grade 021116
Hypokalemia — Grade 0 - Grade 100000
Hypokalemia — Grade 0 - Grade 201442
Hypokalemia — Grade 0 - Grade 300000
Hypokalemia — Grade 1 - Grade 000000
Hypokalemia — Grade 1 - Grade 100000
Hypokalemia — Grade 1 - Grade 200000
Hypokalemia — Grade 1 - Grade 300000
Hypokalemia — Grade 2 - Grade 000000
Hypokalemia — Grade 2 - Grade 100000
Hypokalemia — Grade 2 - Grade 210001
Hypokalemia — Grade 2 - Grade 301000
Hypokalemia — Grade 3 - Grade 000000
Hypokalemia — Grade 3 - Grade 100000
Hypokalemia — Grade 3 - Grade 200000
Hypokalemia — Grade 3 - Grade 300000
Hypokalemia — Grade 4 - Grade 000000
Hypokalemia — Grade 4 - Grade 100000
Hypokalemia — Grade 4 - Grade 200000
Hypokalemia — Grade 4 - Grade 300000
Hypokalemia — Grade 4 - Grade 400000
Hypokalemia — Grade 0 - Grade 400000
Hypokalemia — Grade 1 - Grade 400000
Hypokalemia — Grade 2 - Grade 400000
Hypokalemia — Grade 3 - Grade 400000
Hypokalemia — Missing00000
Hypokalemia — Low - Grade 000000
Hypokalemia — Normal - Grade 000000
Hypokalemia — Normal - Grade 100000
Hypokalemia — Normal - Grade 200000
Hypokalemia — Normal - Grade 300000
Hypokalemia — High - Grade 000000
Hypokalemia — High - Grade 100000
Hypokalemia — High - Grade 200000
Hypokalemia — High - Grade 300000
Hypomagnesemia — Grade 0 - Grade 012347
Hypomagnesemia — Grade 0 - Grade 110102
Hypomagnesemia — Grade 0 - Grade 200000
Hypomagnesemia — Grade 0 - Grade 300000
Hypomagnesemia — Grade 1 - Grade 000000
Hypomagnesemia — Grade 1 - Grade 111110
Hypomagnesemia — Grade 1 - Grade 200000
Hypomagnesemia — Grade 1 - Grade 300000
Hypomagnesemia — Grade 2 - Grade 000000
Hypomagnesemia — Grade 2 - Grade 100000
Hypomagnesemia — Grade 2 - Grade 200000
Hypomagnesemia — Grade 2 - Grade 300000
Hypomagnesemia — Grade 3 - Grade 000000
Hypomagnesemia — Grade 3 - Grade 100000
Hypomagnesemia — Grade 3 - Grade 200000
Hypomagnesemia — Grade 3 - Grade 300000
Hypomagnesemia — Grade 4 - Grade 000000
Hypomagnesemia — Grade 4 - Grade 100000
Hypomagnesemia — Grade 4 - Grade 200000
Hypomagnesemia — Grade 4 - Grade 300000
Hypomagnesemia — Grade 4 - Grade 400000
Hypomagnesemia — Grade 0 - Grade 400000
Hypomagnesemia — Grade 1 - Grade 400000
Hypomagnesemia — Grade 2 - Grade 400000
Hypomagnesemia — Grade 3 - Grade 400000
Hypomagnesemia — Missing00000
Hypomagnesemia — Low - Grade 000000
Hypomagnesemia — Normal - Grade 000000
Hypomagnesemia — Normal - Grade 100000
Hypomagnesemia — Normal - Grade 200000
Hypomagnesemia — Normal - Grade 300000
Hypomagnesemia — High - Grade 000000
Hypomagnesemia — High - Grade 100000
Hypomagnesemia — High - Grade 200000
Hypomagnesemia — High - Grade 300000
Hyponatremia — Grade 0 - Grade 020112
Hyponatremia — Grade 0 - Grade 102311
Hyponatremia — Grade 0 - Grade 200000
Hyponatremia — Grade 0 - Grade 301023
Hyponatremia — Grade 1 - Grade 010001
Hyponatremia — Grade 1 - Grade 100001
Hyponatremia — Grade 1 - Grade 200000
Hyponatremia — Grade 1 - Grade 300101
Hyponatremia — Grade 2 - Grade 000000
Hyponatremia — Grade 2 - Grade 100000
Hyponatremia — Grade 2 - Grade 200000
Hyponatremia — Grade 2 - Grade 300000
Hyponatremia — Grade 3 - Grade 000000
Hyponatremia — Grade 3 - Grade 100000
Hyponatremia — Grade 3 - Grade 200000
Hyponatremia — Grade 3 - Grade 300000
Hyponatremia — Grade 4 - Grade 000000
Hyponatremia — Grade 4 - Grade 100010
Hyponatremia — Grade 4 - Grade 200000
Hyponatremia — Grade 4 - Grade 300000
Hyponatremia — Grade 4 - Grade 400000
Hyponatremia — Grade 0 - Grade 400000
Hyponatremia — Grade 1 - Grade 400000
Hyponatremia — Grade 2 - Grade 400000
Hyponatremia — Grade 3 - Grade 400000
Hyponatremia — Missing00000
Hyponatremia — Low - Grade 000000
Hyponatremia — Normal - Grade 000000
Hyponatremia — Normal - Grade 100000
Hyponatremia — Normal - Grade 200000
Hyponatremia — Normal - Grade 300000
Hyponatremia — High - Grade 000000
Hyponatremia — High - Grade 100000
Hyponatremia — High - Grade 200000
Hyponatremia — High - Grade 300000
Lymphocyte count decreased — Grade 0 - Grade 001131
Lymphocyte count decreased — Grade 0 - Grade 100001
Lymphocyte count decreased — Grade 0 - Grade 200110
Lymphocyte count decreased — Grade 0 - Grade 321301
Lymphocyte count decreased — Grade 1 - Grade 000000
Lymphocyte count decreased — Grade 1 - Grade 100000
Lymphocyte count decreased — Grade 1 - Grade 200000
Lymphocyte count decreased — Grade 1 - Grade 301003
Lymphocyte count decreased — Grade 2 - Grade 000000
Lymphocyte count decreased — Grade 2 - Grade 100000
Lymphocyte count decreased — Grade 2 - Grade 200000
Lymphocyte count decreased — Grade 2 - Grade 310011
Lymphocyte count decreased — Grade 3 - Grade 000000
Lymphocyte count decreased — Grade 3 - Grade 100000
Lymphocyte count decreased — Grade 3 - Grade 200000
Lymphocyte count decreased — Grade 3 - Grade 300000
Lymphocyte count decreased — Grade 4 - Grade 000000
Lymphocyte count decreased — Grade 4 - Grade 100000
Lymphocyte count decreased — Grade 4 - Grade 200000
Lymphocyte count decreased — Grade 4 - Grade 300000
Lymphocyte count decreased — Grade 4 - Grade 400000
Lymphocyte count decreased — Grade 0 - Grade 400000
Lymphocyte count decreased — Grade 1 - Grade 400000
Lymphocyte count decreased — Grade 2 - Grade 400002
Lymphocyte count decreased — Grade 3 - Grade 400000
Lymphocyte count decreased — Missing00000
Lymphocyte count decreased — Low - Grade 000000
Lymphocyte count decreased — Normal - Grade 000000
Lymphocyte count decreased — Normal - Grade 100000
Lymphocyte count decreased — Normal - Grade 200000
Lymphocyte count decreased — Normal - Grade 300000
Lymphocyte count decreased — High - Grade 000000
Lymphocyte count decreased — High - Grade 100000
Lymphocyte count decreased — High - Grade 200000
Lymphocyte count decreased — High - Grade 300000
Platelet count decreased — Grade 0 - Grade 011224
Platelet count decreased — Grade 0 - Grade 112232
Platelet count decreased — Grade 0 - Grade 200002
Platelet count decreased — Grade 0 - Grade 300000
Platelet count decreased — Grade 1 - Grade 000000
Platelet count decreased — Grade 1 - Grade 100000
Platelet count decreased — Grade 1 - Grade 210101
Platelet count decreased — Grade 1 - Grade 300000
Platelet count decreased — Grade 2 - Grade 000000
Platelet count decreased — Grade 2 - Grade 100000
Platelet count decreased — Grade 2 - Grade 200000
Platelet count decreased — Grade 2 - Grade 300000
Platelet count decreased — Grade 3 - Grade 000000
Platelet count decreased — Grade 3 - Grade 100000
Platelet count decreased — Grade 3 - Grade 200000
Platelet count decreased — Grade 3 - Grade 300000
Platelet count decreased — Grade 4 - Grade 000000
Platelet count decreased — Grade 4 - Grade 100000
Platelet count decreased — Grade 4 - Grade 200000
Platelet count decreased — Grade 4 - Grade 300000
Platelet count decreased — Grade 4 - Grade 400000
Platelet count decreased — Grade 0 - Grade 400000
Platelet count decreased — Grade 1 - Grade 400000
Platelet count decreased — Grade 2 - Grade 400000
Platelet count decreased — Grade 3 - Grade 400000
Platelet count decreased — Missing00000
Platelet count decreased — Low - Grade 000000
Platelet count decreased — Normal - Grade 000000
Platelet count decreased — Normal - Grade 100000
Platelet count decreased — Normal - Grade 200000
Platelet count decreased — Normal - Grade 300000
Platelet count decreased — High - Grade 000000
Platelet count decreased — High - Grade 100000
Platelet count decreased — High - Grade 200000
Platelet count decreased — High - Grade 300000
White blood cell decreased — Grade 0 - Grade 001133
White blood cell decreased — Grade 0 - Grade 100010
White blood cell decreased — Grade 0 - Grade 221203
White blood cell decreased — Grade 0 - Grade 311211
White blood cell decreased — Grade 1 - Grade 000000
White blood cell decreased — Grade 1 - Grade 100001
White blood cell decreased — Grade 1 - Grade 200000
White blood cell decreased — Grade 1 - Grade 300000
White blood cell decreased — Grade 2 - Grade 000000
White blood cell decreased — Grade 2 - Grade 100000
White blood cell decreased — Grade 2 - Grade 200000
White blood cell decreased — Grade 2 - Grade 300000
White blood cell decreased — Grade 3 - Grade 000000
White blood cell decreased — Grade 3 - Grade 100000
White blood cell decreased — Grade 3 - Grade 200000
White blood cell decreased — Grade 3 - Grade 300000
White blood cell decreased — Grade 4 - Grade 000000
White blood cell decreased — Grade 4 - Grade 100000
White blood cell decreased — Grade 4 - Grade 200000
White blood cell decreased — Grade 4 - Grade 300000
White blood cell decreased — Grade 4 - Grade 400000
White blood cell decreased — Grade 0 - Grade 400001
White blood cell decreased — Grade 1 - Grade 400000
White blood cell decreased — Grade 2 - Grade 400000
White blood cell decreased — Grade 3 - Grade 400000
White blood cell decreased — Missing00000
White blood cell decreased — Low - Grade 000000
White blood cell decreased — Normal - Grade 000000
White blood cell decreased — Normal - Grade 100000
White blood cell decreased — Normal - Grade 200000
White blood cell decreased — Normal - Grade 300000
White blood cell decreased — High - Grade 000000
White blood cell decreased — High - Grade 100000
White blood cell decreased — High - Grade 200000
White blood cell decreased — High - Grade 300000
Activated partial thromboplastin time prolonged — Grade 0 - Grade 011215
Activated partial thromboplastin time prolonged — Grade 0 - Grade 111120
Activated partial thromboplastin time prolonged — Grade 0 - Grade 210000
Activated partial thromboplastin time prolonged — Grade 0 - Grade 300100
Activated partial thromboplastin time prolonged — Grade 1 - Grade 000000
Activated partial thromboplastin time prolonged — Grade 1 - Grade 101002
Activated partial thromboplastin time prolonged — Grade 1 - Grade 200000
Activated partial thromboplastin time prolonged — Grade 1 - Grade 300000
Activated partial thromboplastin time prolonged — Grade 2 - Grade 000000
Activated partial thromboplastin time prolonged — Grade 2 - Grade 100001
Activated partial thromboplastin time prolonged — Grade 2 - Grade 200000
Activated partial thromboplastin time prolonged — Grade 2 - Grade 300010
Activated partial thromboplastin time prolonged — Grade 3 - Grade 000000
Activated partial thromboplastin time prolonged — Grade 3 - Grade 100000
Activated partial thromboplastin time prolonged — Grade 3 - Grade 200000
Activated partial thromboplastin time prolonged — Grade 3 - Grade 300000
Activated partial thromboplastin time prolonged — Grade 4 - Grade 000000
Activated partial thromboplastin time prolonged — Grade 4 - Grade 100000
Activated partial thromboplastin time prolonged — Grade 4 - Grade 200000
Activated partial thromboplastin time prolonged — Grade 4 - Grade 300000
Activated partial thromboplastin time prolonged — Grade 4 - Grade 400000
Activated partial thromboplastin time prolonged — Grade 0 - Grade 400000
Activated partial thromboplastin time prolonged — Grade 1 - Grade 400000
Activated partial thromboplastin time prolonged — Grade 2 - Grade 400000
Activated partial thromboplastin time prolonged — Grade 3 - Grade 400000
Activated partial thromboplastin time prolonged — Missing00111
Activated partial thromboplastin time prolonged — Low - Grade 000000
Activated partial thromboplastin time prolonged — Normal - Grade 000000
Activated partial thromboplastin time prolonged — Normal - Grade 100000
Activated partial thromboplastin time prolonged — Normal - Grade 200000
Activated partial thromboplastin time prolonged — Normal - Grade 300000
Activated partial thromboplastin time prolonged — High - Grade 000000
Activated partial thromboplastin time prolonged — High - Grade 100000
Activated partial thromboplastin time prolonged — High - Grade 200000
Activated partial thromboplastin time prolonged — High - Grade 300000
Alanine aminotransferase increased — Grade 0 - Grade 000000
Alanine aminotransferase increased — Grade 0 - Grade 100000
Alanine aminotransferase increased — Grade 0 - Grade 200000
Alanine aminotransferase increased — Grade 0 - Grade 300000
Alanine aminotransferase increased — Grade 1 - Grade 000000
Alanine aminotransferase increased — Grade 1 - Grade 100000
Alanine aminotransferase increased — Grade 1 - Grade 200000
Alanine aminotransferase increased — Grade 1 - Grade 300000
Alanine aminotransferase increased — Grade 2 - Grade 000000
Alanine aminotransferase increased — Grade 2 - Grade 100000
Alanine aminotransferase increased — Grade 2 - Grade 200000
Alanine aminotransferase increased — Grade 2 - Grade 300000
Alanine aminotransferase increased — Grade 3 - Grade 000000
Alanine aminotransferase increased — Grade 3 - Grade 100000
Alanine aminotransferase increased — Grade 3 - Grade 200000
Alanine aminotransferase increased — Grade 3 - Grade 300000
Alanine aminotransferase increased — Grade 4 - Grade 000000
Alanine aminotransferase increased — Grade 4 - Grade 100000
Alanine aminotransferase increased — Grade 4 - Grade 200000
Alanine aminotransferase increased — Grade 4 - Grade 300000
Alanine aminotransferase increased — Grade 4 - Grade 400000
Alanine aminotransferase increased — Grade 0 - Grade 400000
Alanine aminotransferase increased — Grade 1 - Grade 400000
Alanine aminotransferase increased — Grade 2 - Grade 400000
Alanine aminotransferase increased — Grade 3 - Grade 400000
Alanine aminotransferase increased — Missing00000
Alanine aminotransferase increased — Low - Grade 000010
Alanine aminotransferase increased — Normal - Grade 002113
Alanine aminotransferase increased — Normal - Grade 131314
Alanine aminotransferase increased — Normal - Grade 200021
Alanine aminotransferase increased — Normal - Grade 300100
Alanine aminotransferase increased — High - Grade 000000
Alanine aminotransferase increased — High - Grade 100001
Alanine aminotransferase increased — High - Grade 200000
Alanine aminotransferase increased — High - Grade 300000
Alkaline phosphatase increased — Grade 0 - Grade 000000
Alkaline phosphatase increased — Grade 0 - Grade 100000
Alkaline phosphatase increased — Grade 0 - Grade 200000
Alkaline phosphatase increased — Grade 0 - Grade 300000
Alkaline phosphatase increased — Grade 1 - Grade 000000
Alkaline phosphatase increased — Grade 1 - Grade 100000
Alkaline phosphatase increased — Grade 1 - Grade 200000
Alkaline phosphatase increased — Grade 1 - Grade 300000
Alkaline phosphatase increased — Grade 2 - Grade 000000
Alkaline phosphatase increased — Grade 2 - Grade 100000
Alkaline phosphatase increased — Grade 2 - Grade 200000
Alkaline phosphatase increased — Grade 2 - Grade 300000
Alkaline phosphatase increased — Grade 3 - Grade 000000
Alkaline phosphatase increased — Grade 3 - Grade 100000
Alkaline phosphatase increased — Grade 3 - Grade 200000
Alkaline phosphatase increased — Grade 3 - Grade 300000
Alkaline phosphatase increased — Grade 4 - Grade 000000
Alkaline phosphatase increased — Grade 4 - Grade 100000
Alkaline phosphatase increased — Grade 4 - Grade 200000
Alkaline phosphatase increased — Grade 4 - Grade 300000
Alkaline phosphatase increased — Grade 4 - Grade 400000
Alkaline phosphatase increased — Grade 0 - Grade 400000
Alkaline phosphatase increased — Grade 1 - Grade 400000
Alkaline phosphatase increased — Grade 2 - Grade 400000
Alkaline phosphatase increased — Grade 3 - Grade 400000
Alkaline phosphatase increased — Missing00000
Alkaline phosphatase increased — Low - Grade 000000
Alkaline phosphatase increased — Normal - Grade 002012
Alkaline phosphatase increased — Normal - Grade 100301
Alkaline phosphatase increased — Normal - Grade 200110
Alkaline phosphatase increased — Normal - Grade 300000
Alkaline phosphatase increased — High - Grade 030124
Alkaline phosphatase increased — High - Grade 100002
Alkaline phosphatase increased — High - Grade 201010
Alkaline phosphatase increased — High - Grade 300000
Aspartate aminotransferase increased — Grade 0 - Grade 000000
Aspartate aminotransferase increased — Grade 0 - Grade 100000
Aspartate aminotransferase increased — Grade 0 - Grade 200000
Aspartate aminotransferase increased — Grade 0 - Grade 300000
Aspartate aminotransferase increased — Grade 1 - Grade 000000
Aspartate aminotransferase increased — Grade 1 - Grade 100000
Aspartate aminotransferase increased — Grade 1 - Grade 200000
Aspartate aminotransferase increased — Grade 1 - Grade 300000
Aspartate aminotransferase increased — Grade 2 - Grade 000000
Aspartate aminotransferase increased — Grade 2 - Grade 100000
Aspartate aminotransferase increased — Grade 2 - Grade 200000
Aspartate aminotransferase increased — Grade 2 - Grade 300000
Aspartate aminotransferase increased — Grade 3 - Grade 000000
Aspartate aminotransferase increased — Grade 3 - Grade 100000
Aspartate aminotransferase increased — Grade 3 - Grade 200000
Aspartate aminotransferase increased — Grade 3 - Grade 300000
Aspartate aminotransferase increased — Grade 4 - Grade 000000
Aspartate aminotransferase increased — Grade 4 - Grade 100000
Aspartate aminotransferase increased — Grade 4 - Grade 200000
Aspartate aminotransferase increased — Grade 4 - Grade 300000
Aspartate aminotransferase increased — Grade 4 - Grade 400000
Aspartate aminotransferase increased — Grade 0 - Grade 400000
Aspartate aminotransferase increased — Grade 1 - Grade 400000
Aspartate aminotransferase increased — Grade 2 - Grade 400000
Aspartate aminotransferase increased — Grade 3 - Grade 400000
Aspartate aminotransferase increased — Missing00000
Aspartate aminotransferase increased — Low - Grade 000100
Aspartate aminotransferase increased — Normal - Grade 001001
Aspartate aminotransferase increased — Normal - Grade 112324
Aspartate aminotransferase increased — Normal - Grade 200011
Aspartate aminotransferase increased — Normal - Grade 300110
Aspartate aminotransferase increased — High - Grade 000000
Aspartate aminotransferase increased — High - Grade 120012
Aspartate aminotransferase increased — High - Grade 200000
Aspartate aminotransferase increased — High - Grade 300001
Blood bilirubin increased — Grade 0 - Grade 000000
Blood bilirubin increased — Grade 0 - Grade 100000
Blood bilirubin increased — Grade 0 - Grade 200000
Blood bilirubin increased — Grade 0 - Grade 300000
Blood bilirubin increased — Grade 1 - Grade 000000
Blood bilirubin increased — Grade 1 - Grade 100000
Blood bilirubin increased — Grade 1 - Grade 200000
Blood bilirubin increased — Grade 1 - Grade 300000
Blood bilirubin increased — Grade 2 - Grade 000000
Blood bilirubin increased — Grade 2 - Grade 100000
Blood bilirubin increased — Grade 2 - Grade 200000
Blood bilirubin increased — Grade 2 - Grade 300000
Blood bilirubin increased — Grade 3 - Grade 000000
Blood bilirubin increased — Grade 3 - Grade 100000
Blood bilirubin increased — Grade 3 - Grade 200000
Blood bilirubin increased — Grade 3 - Grade 300000
Blood bilirubin increased — Grade 4 - Grade 000000
Blood bilirubin increased — Grade 4 - Grade 100000
Blood bilirubin increased — Grade 4 - Grade 200000
Blood bilirubin increased — Grade 4 - Grade 300000
Blood bilirubin increased — Grade 4 - Grade 400000
Blood bilirubin increased — Grade 0 - Grade 400000
Blood bilirubin increased — Grade 1 - Grade 400000
Blood bilirubin increased — Grade 2 - Grade 400000
Blood bilirubin increased — Grade 3 - Grade 400000
Blood bilirubin increased — Missing00000
Blood bilirubin increased — Low - Grade 000000
Blood bilirubin increased — Normal - Grade 011225
Blood bilirubin increased — Normal - Grade 121231
Blood bilirubin increased — Normal - Grade 201101
Blood bilirubin increased — Normal - Grade 300001
Blood bilirubin increased — High - Grade 000000
Blood bilirubin increased — High - Grade 100001
Blood bilirubin increased — High - Grade 200000
Blood bilirubin increased — High - Grade 300000
Creatinine increased — Grade 0 - Grade 022445
Creatinine increased — Grade 0 - Grade 110010
Creatinine increased — Grade 0 - Grade 200002
Creatinine increased — Grade 0 - Grade 300000
Creatinine increased — Grade 1 - Grade 000000
Creatinine increased — Grade 1 - Grade 101101
Creatinine increased — Grade 1 - Grade 200000
Creatinine increased — Grade 1 - Grade 300000
Creatinine increased — Grade 2 - Grade 000000
Creatinine increased — Grade 2 - Grade 100000
Creatinine increased — Grade 2 - Grade 200001
Creatinine increased — Grade 2 - Grade 300000
Creatinine increased — Grade 3 - Grade 000000
Creatinine increased — Grade 3 - Grade 100000
Creatinine increased — Grade 3 - Grade 200000
Creatinine increased — Grade 3 - Grade 300000
Creatinine increased — Grade 4 - Grade 000000
Creatinine increased — Grade 4 - Grade 100000
Creatinine increased — Grade 4 - Grade 200000
Creatinine increased — Grade 4 - Grade 300000
Creatinine increased — Grade 4 - Grade 400000
Creatinine increased — Grade 0 - Grade 400000
Creatinine increased — Grade 1 - Grade 400000
Creatinine increased — Grade 2 - Grade 400000
Creatinine increased — Grade 3 - Grade 400000
Creatinine increased — Missing00000
Creatinine increased — Low - Grade 000000
Creatinine increased — Normal - Grade 000000
Creatinine increased — Normal - Grade 100000
Creatinine increased — Normal - Grade 200000
Creatinine increased — Normal - Grade 300000
Creatinine increased — High - Grade 000000
Creatinine increased — High - Grade 100000
Creatinine increased — High - Grade 200000
Creatinine increased — High - Grade 300000
GGT increased — Grade 0 - Grade 021116
GGT increased — Grade 0 - Grade 111322
GGT increased — Grade 0 - Grade 200111
GGT increased — Grade 0 - Grade 301010
GGT increased — Grade 1 - Grade 000000
GGT increased — Grade 1 - Grade 100000
GGT increased — Grade 1 - Grade 200000
GGT increased — Grade 1 - Grade 300000
GGT increased — Grade 2 - Grade 000000
GGT increased — Grade 2 - Grade 100000
GGT increased — Grade 2 - Grade 200000
GGT increased — Grade 2 - Grade 300000
GGT increased — Grade 3 - Grade 000000
GGT increased — Grade 3 - Grade 100000
GGT increased — Grade 3 - Grade 200000
GGT increased — Grade 3 - Grade 300000
GGT increased — Grade 4 - Grade 000000
GGT increased — Grade 4 - Grade 100000
GGT increased — Grade 4 - Grade 200000
GGT increased — Grade 4 - Grade 300000
GGT increased — Grade 4 - Grade 400000
GGT increased — Grade 0 - Grade 400000
GGT increased — Grade 1 - Grade 400000
GGT increased — Grade 2 - Grade 400000
GGT increased — Grade 3 - Grade 400000
GGT increased — Missing00000
GGT increased — Low - Grade 000000
GGT increased — Normal - Grade 000000
GGT increased — Normal - Grade 100000
GGT increased — Normal - Grade 200000
GGT increased — Normal - Grade 300000
GGT increased — High - Grade 000000
GGT increased — High - Grade 100000
GGT increased — High - Grade 200000
GGT increased — High - Grade 300000
Hemoglobin increased — Grade 0 - Grade 033559
Hemoglobin increased — Grade 0 - Grade 100000
Hemoglobin increased — Grade 0 - Grade 200000
Hemoglobin increased — Grade 0 - Grade 300000
Hemoglobin increased — Grade 1 - Grade 000000
Hemoglobin increased — Grade 1 - Grade 100000
Hemoglobin increased — Grade 1 - Grade 200000
Hemoglobin increased — Grade 1 - Grade 300000
Hemoglobin increased — Grade 2 - Grade 000000
Hemoglobin increased — Grade 2 - Grade 100000
Hemoglobin increased — Grade 2 - Grade 200000
Hemoglobin increased — Grade 2 - Grade 300000
Hemoglobin increased — Grade 3 - Grade 000000
Hemoglobin increased — Grade 3 - Grade 100000
Hemoglobin increased — Grade 3 - Grade 200000
Hemoglobin increased — Grade 3 - Grade 300000
Hemoglobin increased — Grade 4 - Grade 000000
Hemoglobin increased — Grade 4 - Grade 100000
Hemoglobin increased — Grade 4 - Grade 200000
Hemoglobin increased — Grade 4 - Grade 300000
Hemoglobin increased — Grade 4 - Grade 400000
Hemoglobin increased — Grade 0 - Grade 400000
Hemoglobin increased — Grade 1 - Grade 400000
Hemoglobin increased — Grade 2 - Grade 400000
Hemoglobin increased — Grade 3 - Grade 400000
Hemoglobin increased — Missing00000
Hemoglobin increased — Low - Grade 000000
Hemoglobin increased — Normal - Grade 000000
Hemoglobin increased — Normal - Grade 100000
Hemoglobin increased — Normal - Grade 200000
Hemoglobin increased — Normal - Grade 300000
Hemoglobin increased — High - Grade 000000
Hemoglobin increased — High - Grade 100000
Hemoglobin increased — High - Grade 200000
Hemoglobin increased — High - Grade 300000
Hyperkalemia — Grade 0 - Grade 033558
Hyperkalemia — Grade 0 - Grade 100001
Hyperkalemia — Grade 0 - Grade 200000
Hyperkalemia — Grade 0 - Grade 300000
Hyperkalemia — Grade 1 - Grade 000000
Hyperkalemia — Grade 1 - Grade 100000
Hyperkalemia — Grade 1 - Grade 200000
Hyperkalemia — Grade 1 - Grade 300000
Hyperkalemia — Grade 2 - Grade 000000
Hyperkalemia — Grade 2 - Grade 100000
Hyperkalemia — Grade 2 - Grade 200000
Hyperkalemia — Grade 2 - Grade 300000
Hyperkalemia — Grade 3 - Grade 000000
Hyperkalemia — Grade 3 - Grade 100000
Hyperkalemia — Grade 3 - Grade 200000
Hyperkalemia — Grade 3 - Grade 300000
Hyperkalemia — Grade 4 - Grade 000000
Hyperkalemia — Grade 4 - Grade 100000
Hyperkalemia — Grade 4 - Grade 200000
Hyperkalemia — Grade 4 - Grade 300000
Hyperkalemia — Grade 4 - Grade 400000
Hyperkalemia — Grade 0 - Grade 400000
Hyperkalemia — Grade 1 - Grade 400000
Hyperkalemia — Grade 2 - Grade 400000
Hyperkalemia — Grade 3 - Grade 400000
Hyperkalemia — Missing00000
Hyperkalemia — Low - Grade 000000
Hyperkalemia — Normal - Grade 000000
Hyperkalemia — Normal - Grade 100000
Hyperkalemia — Normal - Grade 200000
Hyperkalemia — Normal - Grade 300000
Hyperkalemia — High - Grade 000000
Hyperkalemia — High - Grade 100000
Hyperkalemia — High - Grade 200000
Hyperkalemia — High - Grade 300000
Hypermagnesemia — Grade 0 - Grade 033459
Hypermagnesemia — Grade 0 - Grade 100100
Hypermagnesemia — Grade 0 - Grade 200000
Hypermagnesemia — Grade 0 - Grade 300000
Hypermagnesemia — Grade 1 - Grade 000000
Hypermagnesemia — Grade 1 - Grade 100000
Hypermagnesemia — Grade 1 - Grade 200000
Hypermagnesemia — Grade 1 - Grade 300000
Hypermagnesemia — Grade 2 - Grade 000000
Hypermagnesemia — Grade 2 - Grade 100000
Hypermagnesemia — Grade 2 - Grade 200000
Hypermagnesemia — Grade 2 - Grade 300000
Hypermagnesemia — Grade 3 - Grade 000000
Hypermagnesemia — Grade 3 - Grade 100000
Hypermagnesemia — Grade 3 - Grade 200000
Hypermagnesemia — Grade 3 - Grade 300000
Hypermagnesemia — Grade 4 - Grade 000000
Hypermagnesemia — Grade 4 - Grade 100000
Hypermagnesemia — Grade 4 - Grade 200000
Hypermagnesemia — Grade 4 - Grade 300000
Hypermagnesemia — Grade 4 - Grade 400000
Hypermagnesemia — Grade 0 - Grade 400000
Hypermagnesemia — Grade 1 - Grade 400000
Hypermagnesemia — Grade 2 - Grade 400000
Hypermagnesemia — Grade 3 - Grade 400000
Hypermagnesemia — Missing00000
Hypermagnesemia — Low - Grade 000000
Hypermagnesemia — Normal - Grade 000000
Hypermagnesemia — Normal - Grade 100000
Hypermagnesemia — Normal - Grade 200000
Hypermagnesemia — Normal - Grade 300000
Hypermagnesemia — High - Grade 000000
Hypermagnesemia — High - Grade 100000
Hypermagnesemia — High - Grade 200000
Hypermagnesemia — High - Grade 300000
Hypernatremia — Grade 0 - Grade 023559
Hypernatremia — Grade 0 - Grade 110000
Hypernatremia — Grade 0 - Grade 200000
Hypernatremia — Grade 0 - Grade 300000
Hypernatremia — Grade 1 - Grade 000000
Hypernatremia — Grade 1 - Grade 100000
Hypernatremia — Grade 1 - Grade 200000
Hypernatremia — Grade 1 - Grade 300000
Hypernatremia — Grade 2 - Grade 000000
Hypernatremia — Grade 2 - Grade 100000
Hypernatremia — Grade 2 - Grade 200000
Hypernatremia — Grade 2 - Grade 300000
Hypernatremia — Grade 3 - Grade 000000
Hypernatremia — Grade 3 - Grade 100000
Hypernatremia — Grade 3 - Grade 200000
Hypernatremia — Grade 3 - Grade 300000
Hypernatremia — Grade 4 - Grade 000000
Hypernatremia — Grade 4 - Grade 100000
Hypernatremia — Grade 4 - Grade 200000
Hypernatremia — Grade 4 - Grade 300000
Hypernatremia — Grade 4 - Grade 400000
Hypernatremia — Grade 0 - Grade 400000
Hypernatremia — Grade 1 - Grade 400000
Hypernatremia — Grade 2 - Grade 400000
Hypernatremia — Grade 3 - Grade 400000
Hypernatremia — Missing00000
Hypernatremia — Low - Grade 000000
Hypernatremia — Normal - Grade 000000
Hypernatremia — Normal - Grade 100000
Hypernatremia — Normal - Grade 200000
Hypernatremia — Normal - Grade 300000
Hypernatremia — High - Grade 000000
Hypernatremia — High - Grade 100000
Hypernatremia — High - Grade 200000
Hypernatremia — High - Grade 300000
INR increased — Grade 0 - Grade 021332
INR increased — Grade 0 - Grade 100003
INR increased — Grade 0 - Grade 200000
INR increased — Grade 0 - Grade 301000
INR increased — Grade 1 - Grade 000000
INR increased — Grade 1 - Grade 100021
INR increased — Grade 1 - Grade 200102
INR increased — Grade 1 - Grade 300000
INR increased — Grade 2 - Grade 000000
INR increased — Grade 2 - Grade 100000
INR increased — Grade 2 - Grade 211101
INR increased — Grade 2 - Grade 300000
INR increased — Grade 3 - Grade 000000
INR increased — Grade 3 - Grade 100000
INR increased — Grade 3 - Grade 200000
INR increased — Grade 3 - Grade 300000
INR increased — Grade 4 - Grade 000000
INR increased — Grade 4 - Grade 100000
INR increased — Grade 4 - Grade 200000
INR increased — Grade 4 - Grade 300000
INR increased — Grade 4 - Grade 400000
INR increased — Grade 0 - Grade 400000
INR increased — Grade 1 - Grade 400000
INR increased — Grade 2 - Grade 400000
INR increased — Grade 3 - Grade 400000
INR increased — Missing00000
INR increased — Low - Grade 000000
INR increased — Normal - Grade 000000
INR increased — Normal - Grade 100000
INR increased — Normal - Grade 200000
INR increased — Normal - Grade 300000
INR increased — High - Grade 000000
INR increased — High - Grade 100000
INR increased — High - Grade 200000
INR increased — High - Grade 300000
Lymphocyte count increased — Grade 0 - Grade 033559
Lymphocyte count increased — Grade 0 - Grade 100000
Lymphocyte count increased — Grade 0 - Grade 200000
Lymphocyte count increased — Grade 0 - Grade 300000
Lymphocyte count increased — Grade 1 - Grade 000000
Lymphocyte count increased — Grade 1 - Grade 100000
Lymphocyte count increased — Grade 1 - Grade 200000
Lymphocyte count increased — Grade 1 - Grade 300000
Lymphocyte count increased — Grade 2 - Grade 000000
Lymphocyte count increased — Grade 2 - Grade 100000
Lymphocyte count increased — Grade 2 - Grade 200000
Lymphocyte count increased — Grade 2 - Grade 300000
Lymphocyte count increased — Grade 3 - Grade 000000
Lymphocyte count increased — Grade 3 - Grade 100000
Lymphocyte count increased — Grade 3 - Grade 200000
Lymphocyte count increased — Grade 3 - Grade 300000
Lymphocyte count increased — Grade 4 - Grade 000000
Lymphocyte count increased — Grade 4 - Grade 100000
Lymphocyte count increased — Grade 4 - Grade 200000
Lymphocyte count increased — Grade 4 - Grade 300000
Lymphocyte count increased — Grade 4 - Grade 400000
Lymphocyte count increased — Grade 0 - Grade 400000
Lymphocyte count increased — Grade 1 - Grade 400000
Lymphocyte count increased — Grade 2 - Grade 400000
Lymphocyte count increased — Grade 3 - Grade 400000
Lymphocyte count increased — Missing00000
Lymphocyte count increased — Low - Grade 000000
Lymphocyte count increased — Normal - Grade 000000
Lymphocyte count increased — Normal - Grade 100000
Lymphocyte count increased — Normal - Grade 200000
Lymphocyte count increased — Normal - Grade 300000
Lymphocyte count increased — High - Grade 000000
Lymphocyte count increased — High - Grade 100000
Lymphocyte count increased — High - Grade 200000
Lymphocyte count increased — High - Grade 300000
PrimaryInvestigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)

RECIST = Response Evaluation Criteria in Solid Tumors

Time frame:
24 months
Reported as:
Number · Percent of participants
Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)
Percent of participantsWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg
ORR by RECIST0 (0 to 70.8)33.3 (0.8 to 90.6)0 (0 to 70.8)0 (0 to 52.2)0 (0 to 41.0)
immune ORR by iRECIST0 (0 to 70.8)33.3 (0.8 to 90.6)0 (0 to 70.8)0 (0 to 52.2)0 (0 to 41.0)
SecondaryPlasma Concentrations of WTX-330 Cycle 1 - C Max

PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · mcg/ml
Plasma Concentrations of WTX-330 Cycle 1 - C Max
mcg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 1 - C Max0.2773 ± 0.116840.4290 ± 0.294650.8624 ± 0.17688
SecondaryPlasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation

PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · h
Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation
hWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation2.40 ± 3.6372.93 ± 4.5613.26 ± 1.668
SecondaryPlasma Concentrations of WTX-330 Cycle 1 - Half Life

PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · day
Plasma Concentrations of WTX-330 Cycle 1 - Half Life
dayWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 1 - Half Life2.1886 ± 1.233942.7083 ± 1.007543.3463 ± 1.48342
SecondaryPlasma Concentrations of WTX-330 Cycle 1 - AUC

PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

Time frame:
14 days
Reported as:
Mean · day*mcg/ml
Plasma Concentrations of WTX-330 Cycle 1 - AUC
day*mcg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 1 - AUC0.7585 ± 0.503631.1952 ± 0.842431.7270 ± 0.75076
SecondaryPlasma Concentrations of WTX-330 Cycle 2 - C Max

PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · mcg/ml
Plasma Concentrations of WTX-330 Cycle 2 - C Max
mcg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 2 - C Max0.3210 ± 0.049500.6272 ± 0.606131.0748 ± 0.70201
SecondaryPlasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation

PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · h
Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation
hWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation0.30 ± 01.40 ± 1.9922.15 ± 2.136
SecondaryPlasma Concentrations of WTX-330 Cycle 2 - Half Life

PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · day
Plasma Concentrations of WTX-330 Cycle 2 - Half Life
dayWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 2 - Half Life3.3296 ± 0.344542.8809 ± 1.739104.0216 ± 1.06686
SecondaryPlasma Concentrations of WTX-330 Cycle 2 - AUC

PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

Time frame:
14 days
Reported as:
Mean · day*mcg/ml
Plasma Concentrations of WTX-330 Cycle 2 - AUC
day*mcg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of WTX-330 Cycle 2 - AUC1.0247 ± 0.142750.8744 ± 0.514991.8042 ± 0.80145
SecondaryPlasma Concentrations of IL-12 Cycle 1 - C Max

PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · pg/ml
Plasma Concentrations of IL-12 Cycle 1 - C Max
pg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 1 - C Max1434.7 ± 694.102298.0 ± 1434.713022.0 ± 787.48
SecondaryPlasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation

PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · h
Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation
hWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation4.90 ± 1.4735.23 ± 2.0656.48 ± 2.182
SecondaryPlasma Concentrations of IL-12 Cycle 1 - Half Life

PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · day
Plasma Concentrations of IL-12 Cycle 1 - Half Life
dayWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 1 - Half Life3.2138 ± 1.334053.2643 ± 1.266422.4809 ± 0.75436
SecondaryPlasma Concentrations of IL-12 Cycle 1 - AUC

PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

Time frame:
14 days
Reported as:
Mean · day*pg/ml
Plasma Concentrations of IL-12 Cycle 1 - AUC
day*pg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 1 - AUC3221.5 ± 1879.295144.7 ± 3395.295986.4 ± 2336.59
SecondaryPlasma Concentrations of IL-12 Cycle 2 - C Max

PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · pg/ml
Plasma Concentrations of IL-12 Cycle 2 - C Max
pg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 2 - C Max1331.5 ± 26.162165.7 ± 1933.233292.8 ± 2236.70
SecondaryPlasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation

PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · h
Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation
hWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation13.80 ± 13.4350.27 ± 0.0582.95 ± 1.782
SecondaryPlasma Concentrations of IL-12 Cycle 2 - Half Life

PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2

Time frame:
0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Reported as:
Mean · day
Plasma Concentrations of IL-12 Cycle 2 - Half Life
dayWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 2 - Half Life2.2540 ± 0.929053.8541 ± 0.923482.7120 ± 1.54085
SecondaryPlasma Concentrations of IL-12 Cycle 2 - AUC

PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.

Time frame:
14 days
Reported as:
Mean · day*pg/ml
Plasma Concentrations of IL-12 Cycle 2 - AUC
day*pg/mlWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kg
Plasma Concentrations of IL-12 Cycle 2 - AUC3569.4 ± 636.451957.5 ± 635.674349.9 ± 1530.39
SecondaryAntidrug Antibody (ADA) Occurrence

ADA were measured at Baseline and Post Baseline. "Positive" post baseline applies if at least one post-baseline value was positive.

Time frame:
24 months
Reported as:
Count of participants · Participants
Antidrug Antibody (ADA) Occurrence
ParticipantsWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg
ADA at Baseline — Negative23458
ADA at Baseline — Positive10101
ADA at Baseline — Unknown00000
ADA post Baseline — Negative22235
ADA post Baseline — Positive11200
ADA post Baseline — Unknown00124

Adverse events

Collected over AEs were collected from the signing of the ICF for a median duration of 86 days (min 37, max 219). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
WTX-330 Dose Escalation - 0.016 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
WTX-330 Dose Escalation - 0.024 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
WTX-330 Dose Escalation - 0.032 mg/kg0/5 (0%)2/5 (40%)5/5 (100%)
WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg3/5 (60%)3/5 (60%)5/5 (100%)
WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg5/9 (55.6%)8/9 (88.9%)9/9 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg
Cytokine release syndromeImmune system disorders0/31/31/50/54/9
FatigueGeneral disorders0/30/30/50/52/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/30/50/52/9
Adrenocortical insufficiency acuteEndocrine disorders0/30/31/50/50/9
GastritisGastrointestinal disorders0/30/30/51/50/9
SepsisInfections and infestations0/30/30/51/51/9
Urinary tract infectionInfections and infestations0/30/30/51/50/9
Malignant melanoma of sites other than skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/51/50/9
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/51/50/9
NauseaGastrointestinal disorders0/30/30/50/51/9
Most frequent other events
Showing 10 of 122
Most frequent other events
EventWTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg
NauseaGastrointestinal disorders1/31/35/50/53/9
ChillsGeneral disorders1/30/34/52/56/9
Abdominal painGastrointestinal disorders1/32/30/50/50/9
StomatitisGastrointestinal disorders0/32/30/52/51/9
FatigueGeneral disorders2/32/33/51/53/9
PyrexiaGeneral disorders2/31/33/53/54/9
Cytokine release syndromeImmune system disorders1/32/32/53/52/9
Alanine aminotransferase increasedInvestigations2/31/33/51/54/9
Aspartate aminotransferase increasedInvestigations2/31/33/51/54/9
DehydrationMetabolism and nutrition disorders2/30/30/51/50/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)WTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgTotal
Mean63.3 ± 10.2660.6 ± 11.5568.2 ± 7.9065.00 ± 11.0061.8 ± 10.1364.4 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)WTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgTotal
Female2252112
Male1341413
Race (NIH/OMB)
Race (NIH/OMB)(Participants)WTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American101002
White1583421
More than one race000000
Unknown or Not Reported100012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)WTX-330 Dose Escalation - 0.016 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kgWTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kgWTX-330 Dose Escalation - 0.024 mg/kgWTX-330 Dose Escalation - 0.032 mg/kgTotal
Hispanic or Latino200103
Not Hispanic or Latino1592522
Unknown or Not Reported000000
08

Study locations

9 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • Emory Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Mass General Hospital
    Boston, Massachusetts 02114, United States
  • Facility Name: Roswell Park Comprehensive Cancer Care
    Buffalo, New York 14203, United States
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2024, 24 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 71. This study's 24 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Jan 10, 2023
StartActual
Dec 6, 2022
Primary completionActual
Dec 23, 2024
CompletionActual
Feb 5, 2025
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05678998
Lead sponsor
Werewolf Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Dec 6, 2022
Primary completion
Dec 23, 2024
Completion
Feb 5, 2025
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion